Abstract: The present invention relates in general to a method for the reduction of oxygenated compounds of rhenium and technetium and in particular to the reduction of perrhenate or pertechnetate ions.More particularly, the invention relates to reactions for the reduction of the said oxygenated compounds which are carried out in the course of the preparation of complexes of the radionuclides .sup.186 Re, .sup.188 Re and .sup.99m Tc; in these reactions, the radionuclide perrhenate or pertechnetate ion is reduced in the presence of a reducing agent and a ligand which can form a complex with the radionuclide in its reduced oxidation state.

Abstract: The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Abstract: Tablet formulations having a structure comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant, the granulates being compacted together into a tablet with an extra-granular disintegrant and optional extra-granular lubricant and excipients.

Abstract: Disclosed is a novel amylase which mainly forms maltohexaose and maltoheptaose when acts on starch, but does not substantially hydrolyze maltohexaose and a lower molecular oligosaccharide than maltohexaose. The amylase can be prepared from microorganisms of the genus Alcaligenes, and has a relatively-high optimum temperature and thermal stability, as well as a relatively-wide range of optimum pH and pH stability. By using the amylase, saccharide compositions rich in maltohexaose and/or maltoheptaose or those rich in maltohexaitol and/or maltoheptaitol can be readily prepared in an industrial scale, and the saccharide compositions thus obtained can be used in a variety of food products, cosmetics and pharmaceuticals.

Abstract: The invention relates to accurately meterable shaped articles, for example granules or pellets, containing hydrophilic macromolecules, active compounds and optionally further pharmaceutically acceptable structure-forming substances and auxiliaries, the active compound being present in a matrix in dissolved, suspended or emulsified form, and a novel process for the production of these shaped articles, the process being particularly economically and ecologically acceptable, and use of the shaped articles as medicaments, in which the bioavailability, shelf life and tolerability is increased. Using the shaped articles or mixtures according to the invention, intermediates or final products for pharmacy, cosmetics, diagnosis, analysis or dietetics (healthcare) can additionally be advantageously prepared.

Abstract: The present invention relates to a solid pharmaceutical dosage form for oral administration, consisting essentially of(a) at least one active substance,(b) at least one filler,(c) at least one binding agent, and(d) optionally usual auxiliaries,which dosage form, however, does not contain agar;which dosage form is manufactured without applying any compression force to the mixture of the components (a), (b), (c) and (d); andwhich dosage form disintegrates when taken into the mouth within 15 seconds.

Abstract: A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such aprocess are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.

Abstract: The present invention relates to methods of using and compositions containing acrivastine which provide antihistaminic therapeutic benefits while minimizing undesirable central nervous system side effects. According to the present invention, the plasma concentration-response curve for acrivastine's sedative side effects is steeper than that of the plasma concentration-response curve for its antihistamine activity. Accordingly, when the peak blood plasma level of acrivastine is maintained within the levels provided by the present invention composition, the central nervous side effects are minimized while the antihistaminic effects are optimized.

Abstract: The present invention is to a tablet formulation, being a medicament for oral administration for the treatment of bacterial infections, the tablet comprising a compacted mixture of 750-950 mg of amoxycillin and a quantity of clavulanate in a weight ratio of amoxycillin:clavulanate between 6:1 to 8:1 inclusive, and having a film coating of polymers which can be applied by aqueous film coating techniques.

Abstract: Sulfoalkyl ether cyclodextrin (SAE-CD) based controlled release pharmaceutical formulations are provided by the present invention. The present solid pharmaceutical formulations consist of a core comprising a physical mixture of one or more SAE-CD derivatives, an optional release rate modifier, a therapeutic agent, a major portion of which is not complexed to the SAE-CD, and an optional release rate modifying coating surrounding the core. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative is used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents. Multi-layered, osmotic pump, coated, and uncoated tablet, minitablet, pellet, micropellet, particle, powder, and granule dosage forms are disclosed herein.

Abstract: The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;(I) carnauba wax in an amount of about 59% to about 81% by weight of Formulation (A); and(ii) a suitable antiadherent in an amount of about 0.25% to about 2.

Abstract: A rapid release tablet involves as an active ingredient tolfenamic acid or its pharmaceutically acceptable salts having a mean particle size of <10 .mu.m, alginic acid or its pharmaceutically acceptable salts in an amount of 1.5-6.0% by weight, and a superdisintegrant in an amount of at least 6% by weight.

Abstract: Pharmaceutical compositions containing potassium, sodium or Tris salt of oxaprozin as an active agent. The pharmaceutical compositions of the present invention are useful in eliminating or ameliorating pain and in the treatment of inflammation and inflammation associated disorders such as rheumatoid arthritis and osteoarthritis.

Abstract: A dry powder composition comprising budesonide and a carrier substance, both of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.

Abstract: Described herein is a particular type of pharmaceutical tablet, for oral use, which is formed by one or more layers, and is specifically designed for controlled release of active principles that present problems of bio-availability linked to absorption in the gastro-intestinal tract, and in particular active principles that present an erratic and unpredictable absorption linked to the presence or absence of food at the level of the stomach and/or of the first portion of the small intestine, the said pharmaceutical form being characterized in that it is completely coated with one or more films of a biocompatible and biodegradable polymeric material.

Abstract: Disclosed are novel non-reducing saccharide-forming enzyme, and its preparation and uses. The enzyme is obtainable from the culture of microorganisms such as Rhizobium sp. M-11 (FERM BP 4130) and Arthrobacter sp. Q36 (FERM BP-4316), and capable of forming non-reducing saccharides having a trehalose structure when allowed to act on reducing partial starch hydrolysates. Glucoamylase and .alpha.-glucosidase readily yield trehalose when allowed to act on the non-reducing saccharides. These non-reducing saccharides and trehalose are extensively useful in food products, cosmetics and pharmaceuticals.

Abstract: Freeze-dried disintegrating tablets, said tablets containing at least a therapeutic agent, a matrix forming agent and a binding agent, in which the tablets contain more than 20% by weight of a matrix forming agent selected from the group consisting of maltodextrins having a DE value between 12 and 40, isomalt and mixtures thereof, the weight ratio between said matrix forming agent and the binding agent being comprised between 2:1 and 50:1.

Abstract: The present invention is a replacement for petroleum jelly as a base for products suitable for application to the skin. It is comprised of vegetable oil and silica. The vegetable oil is preferably a canola oil and more preferably a high oleic acid/low linolenic acid canola oil. The silica is preferably untreated fumed silica powder. The vegetable oil is preferably present in the range of 50-90% and most preferably 80%. The silica is present in the range of 5-15% and most preferably 10%. Other ingredients which may be added include vitamin E, margarine or butter, starch, and sunscreen. The base of the present invention has a significantly higher melting temperature than petroleum jelly.

Abstract: Hydrodynamic baits for the control of orthopterous insects are disclosed which contain an attractant, a humectant and a gel former. The baits are designed to function in harsh and/or dynamic microclimates such as for example commercial kitchens or outdoor environments subject to typical circadian influences such as temperature and moisture. A further advantage of the disclosed baits is their lack of attractiveness to mammals.

Abstract: The present invention provides nonaqueous compositions comprising a saccharide fatty acid ester and an active compound. The nonaqueous compositions of this invention may be parenterally administered to animals and humans. In particular, the nonaqueous compositions of the present invention are useful for preventing, controlling or treating helminth, acarid or arthropod endo- or ectoparasitic infection or infestation in warm-blooded animals.

Abstract: A medicament for nasal administration to be used for disease prevention or treatment comprising a vaccine or a pharmacologically active peptide compounded with an ion exchange resin or adsorbent resin powder whose mean particle size is not larger than 200 .mu.m.

Abstract: This invention relates to an herb composition which comprises an amount of 30 to 45% by weight of one or more herbs for invigorating of blood circulation, an amount of 55 to 70% by weight of one or more herbs for excreting toxin from human body, and an amount of 0.

Abstract: A compact solid gel is described containing water, that consists of water in a concentration ranging from 15% to 90%, thermoreversible polysaccharides in a concentration ranging from 0.3% to 4%, humectant compounds in a concentration ranging from 4% to 40%, and powder phase in a concentration ranging from 2% to 35%.

Abstract: A cyclodextrin derivative, wherein at least 60 percent of the free hydroxy groups of said cyclodextrin are acylated with acyl groups where at least one of said acyl groups comprise a free carboxylic group.

Abstract: Sparingly water-soluble active compounds, for example medicinal substances, are converted into the dissolved (molecularly disperse) state by dissolving them in a hydrophilic peptide having a molecular weight above 100 D, for example gelatin. The solubility both during storage and during use of the formulation by the user or patient is thereby ensured, without organic solvents or solubilizing agents which cause undesirable side effects being required.

Abstract: A delivery device for delivering an active substance to a patient at a predetermined time after administration comprises a male hydrogel plug engaged in the neck of a female body. An expandable excipient such as a hydrogel powder or a pharmaceutical disintegrant in powder, slug or tablet form is provided beneath the active substance. In contact with an aqueous medium, the excipient absorbs water and swells such as to rapidly expel the active substance and effectively deliver it from the device.

Abstract: A composition providing a relatively slow release of water-soluble drugs, such as apomorphine, for delivery via the sublingual or buccal routes.

Abstract: A dry moisture barrier film coating composition for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, and optionally a flow aid, a colorant, and/or a suspending agent. A liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprises polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent. A method of coating pharmaceutical tablets and the like with a moisture barrier film coating comprises forming a liquid coating solution or dispersion for forming a moisture barrier film coating for pharmaceutical tablets and the like comprising polyvinyl alcohol, soya lecithin, water, and optionally a flow aid, a colorant, and/or a suspending agent, applying the coating solution or dispersion onto the tablets to form a film coating on the tablets, and drying the film coating on the tablets.

Abstract: This invention provides a method for controlling soilborne fungal disease in cultivated field plants such as a peanut crop. Field crop soil is treated with a free-flowing granular fungicide composition which can be applied by aerial means with minimal settling on plant foliage. The granular fungicide composition comprises ammonium bicarbonate and a solid surfactant ingredient, and is effective against soilborne fungi such as a Sclerotinia, Rhizoctonia, Pythium, Fusarium, Phytophthora or Verticillium species.

Abstract: A method for alleviating the symptoms of a cosmetic or dermatologic skin condition is described. An effective amount of a poly(hydroxy acid)/polymer conjugate in a pharmaceutically or cosmetically acceptable vehicle is provided. Topical compositions of the conjugates with another cosmetic or dermatological agent, and compounds of the conjugates having attached physiologically active functional groups, are also provided.

Abstract: The invention relates to accurately meterable shaped articles, for example granules or pellets, containing hydrophilic macromolecules, active compounds and optionally further pharmaceutically acceptable structure-forming substances and auxiliaries, the active compound being present in a matrix in dissolved, suspended or emulsified form, and a novel process for the production of these shaped articles, the process being particularly economically and ecologically acceptable, and use of the shaped articles as medicaments, in which the bioavailability, shelf life and tolerability is increased. Using the shaped articles or mixtures according to the invention, intermediates or final products for pharmacy, cosmetics, diagnosis, analysis or dietetics (healthcare) can additionally be advantageously prepared.

Abstract: Sulfoalkyl ether-cyclodextrin (SAE-CD) based pharmaceutical formulations are provided by the present invention. These formulations comprise SAE-CD derivatives and a therapeutic agent, a major portion of which is not complexed to the SAE-CD. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative can be used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents.

Abstract: This invention provides compositions comprising particulate water-soluble or water-swellable polymer at least partially agglomerated by treatment with at least one polyol, wherein the polyol is present at a level greater than about 10 wt. % based on the total weight of the composition. The particulate water-soluble or water-swellable polymer which has been at least partially agglomerated by treatment with polyol hydrates in water-containing solvents substantially faster than untreated water-soluble or water-swellable polymer, without formation of polymer lumps. The invention further provides an improved process for preparing a toothpaste composition comprising at least one dry, water-soluble or water-swellable polymer, the improvement comprising substituting for the dry, water-soluble or water-swellable polymer, particulate water-soluble or water-swellable polymer which has been at least partially agglomerated by treatment with polyol.

Abstract: The present invention discloses tablet formulations, produced by dry roller compaction comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant. The granulates are compacted together into a tablet with an extra-granular disintegrant, an optional extragranular lubricant and excipients.

Abstract: The present invention discloses tablet formulations, produced by dry roller compaction comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant. The granulates are compacted together into a tablet with an extra-granular disintegrant, an optional extragranular lubricant and excipients.

Abstract: A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

Abstract: A pulsatile drug delivery system comprising of a plurality of particles is able to deliver drug in any desired patterns. A plurality of particles with multi-layer core capable of short-pulse release interlaced with long-duration release is designed for delivery of multi-agents simultaneously or sequentially, or single agent, according to a pre-programmed profile.

Abstract: A body powder composition useful for removing sand adhered to a user's body. The composition comprises a major amount of cornstarch. A related method for removing sand off the body is also disclosed comprising the steps of liberally applying a powder composition containing a major amount of cornstarch to an area of the body having sand adhered thereto; rubbing said composition on said area; and wiping said composition and said sand off the area using one's hands or a towel or the like.

Abstract: A composition for use in the shell of a comestible capsule comprising Gelatin and a plasticiser such as Glycerol together with a further component which forms a secondary matrix for the plasticiser. The provision of this secondary matrix enables the relative amount of the gelatin to the plasticiser to be reduced which shortens disintegration time in the mouth. The further component is typically unbleached potato starch acetate.

Abstract: This invention provides a deodorant composition in a dispensing container which is pressurized with an aerosol propellant. The primary ingredients of a typical product are particulate sodium bicarbonate, ethanol, volatile silicone oil and a suspending agent such as hydrophobic hectorite clay. An invention aerosol deodorant product has a stable particulate sodium bicarbonate suspension phase, and exhibits excellent fluid evacuation properties with a relatively high content of ethanol and low content of aerosol propellant.

Abstract: Microcapsules based on crosslinked plant polyphenols are described. These microcapsules are obtained by the interfacial crosslinking of plant polyphenols, particularly flavonoids. When incorporated in a composition such as a cosmetic, pharmaceutical, dietetic or food composition, these microcapsules make it possible to prevent any impairment of this composition, in particular any color modification, while at the same time preserving the activity, especially the anti-free radical and/or antioxidizing activity, of the plant polyphenols, particularly the flavonoids.

Abstract: A pharmaceutical suspension formulation comprising 0.1 to 40% by weight ##STR1## as the active ingredient; 0.1 to 40% by weight Transcutol; 0.1-99% by weight starch; 0-40% by weight polyethylene glycol, NaOH and water,wherein the mole equivalents of NaOH per mole equivalent of active ingredient is from 0.5 to 1.5 is particularly useful for filling hard gelatin capsules.

Abstract: Ophthalmic preparation for use as artificial tear containing hyaluronate as a viscosity thickener, preferably in the form of sodic salt and having a molecular weight of 500,000 to 4,000,000 daltons, at a concentration of 0.05 to 2% by weight, as well as the following minimum quantities of ionic species: 40 mmol/l sodium ion, 12 mmol/l potassium ion, 0.4 mmol/l calcium ion, 0.4 mmol/l magnesium ion, 50 mmol/l chloride ion, 7 mmol/l phosphate ion and, preferably, 0.7 mmol/l citrate ion. The formulation, which as an osmolarity of 140 to 280 mOsm/l, is useful for the treatment of keratoconjunctivitis sicca and may be administered whenever the use of artifical tears is advisable, e.g. for the treatment of eye irritations caused by environmental conditions or contact lenses.

Abstract: This invention is directed to a homogenous water-in-perfluorochemical stable liquid dispersion for acceptable therapeutic administration of a drug to the lung of an animal. The dispersion includes a perfluorochemical liquid, water, surfactant and drug, wherein the water is homogeneously dispersed in the perfluorochemical to form a stable water-in-perfluorochemical liquid dispersion. The perfluorochemical constitutes greater than 50% by volume of the dispersion, and the drug is contained in the dispersion in an effective therapeutic amount.The invention further includes a method of delivering a drug to the lung of an animal. This aspect of the invention includes administering a stable homogenous water-in-perfluorochemical liquid dispersion to the animal lung or a section thereof. If desired, the method may further include delivering a breathable gas to the lung with a mechanical ventilator during the administration.

Abstract: Pharmaceutical formulations of fluoxetine or an acid addition salt thereof, suitable for manufacturing dispersible tablets by direct compression and comprising, in addition to the active ingredient, the appropriate excipients and coadjuvants, selected from among disintegrants, diluents, lubricants, anti-adherents, sweeteners, flavorings and, optionally, colorants.Said formulations are suitable for manufacturing dispersible tablets which disintegrate in less than three minutes in water at 19.degree. C.-21.degree. C., and are appropriate for treatment of depression.

Abstract: The invention provides novel compositions of matter for delivering water-insoluble steroid drugs suitable for therapeutic use. The invention also provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of .ltoreq.30 .mu.m which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.

Abstract: Compositions for delivery of pharmacologically active agents and methods for their administration are provided. In one embodiment, the compositions include a complex of a polycationic polymer and a pharmacologically active agent in a pharmaceutically acceptable carrier. The compositions in one embodiment permit transport of pharmacologically active compounds across mucosal membranes for systemic delivery. The polycationic polymer may be, for example, a polycationic carbohydrate such as a chitosan or a chitosan salt or derivative. The therapeutic agent a preferred embodiment is a vaccine or a nucleic acid, such as a gene or antisense oligonucleotide. The composition may be provided in different forms such as a solution, dispersion, powder or in the form of microspheres.

Abstract: Iodophore containinga) 20-71% by weight of PVP or poly-N-vinylcaprolactam,b) 20-71% by weight of dextrin of DE 2-40,c) 6-25% by weight of elemental iodine,d) 3-12.5% by weight of iodide ions,and process for its preparation are disclosed.

Abstract: The present invention is a saccharide-based matrix, and the products resulting therefrom, made from a maltodextrin feedstock subjected to conditions which induce flash flow of the maltodextrin so that the matrix possesses a physically or chemically altered structure from the feedstock. The present invention also includes a method of producing the matrix and of making products which take advantage of the unique properties of the matrix.

Abstract: Water-soluble pressure-sensitive adhesives include a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer that is miscible with the polymer. Suitable polymers are solid at room temperature; and have a hydrophilicity as measured by water uptake greater than about 25%; they are liquid at room temperature and have a boiling point higher than about 80.degree. C. The adhesives according to the invention may conveniently be provided in dry film form. Preferred water-soluble pressure-sensitive adhesives of the invention adhere both to mucosal surfaces and to a variety of materials that may constitute a part of a device or prosthesis to be held in a body cavity that has a mucosal lining. Also, a laminated device for the controlled release of a substance within a mucosa-lined body cavity includes the substance dissolved or dispersed in either or both of a water-soluble pressure-sensitive adhesive layer and optionally one or more water-soluble polymer layers.